Compare TRMD & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRMD | ABCL |
|---|---|---|
| Founded | 1889 | 2012 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 2016 | 2020 |
| Metric | TRMD | ABCL |
|---|---|---|
| Price | $34.29 | $12.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $44.50 | $18.00 |
| AVG Volume (30 Days) | 1.5M | ★ 3.2M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 15.02% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $54.24 | N/A |
| Revenue Next Year | N/A | $16.61 |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $19.30 | $2.75 |
| 52 Week High | $43.31 | $14.98 |
| Indicator | TRMD | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 49.60 |
| Support Level | $31.76 | $11.78 |
| Resistance Level | $34.47 | $13.21 |
| Average True Range (ATR) | 1.62 | 0.99 |
| MACD | -0.94 | -0.03 |
| Stochastic Oscillator | 11.62 | 44.84 |
TORM PLC operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha, and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.